HC Wainwright Reaffirms Buy Rating for Flexion Therapeutics (NASDAQ:FLXN)


Share on StockTwits

HC Wainwright restated their buy rating on shares of Flexion Therapeutics (NASDAQ:FLXN) in a research report report published on Wednesday, AnalystRatings.com reports.

FLXN has been the topic of several other reports. Wells Fargo & Company cut their price objective on shares of Flexion Therapeutics from $16.00 to $15.00 and set an overweight rating on the stock in a report on Wednesday, January 27th. Credit Suisse Group cut their price objective on shares of Flexion Therapeutics from $19.00 to $18.00 and set an outperform rating on the stock in a report on Wednesday, March 17th. Finally, Zacks Investment Research upgraded shares of Flexion Therapeutics from a sell rating to a hold rating in a report on Tuesday, March 16th. Two research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of Buy and an average price target of $19.75.

Shares of FLXN stock opened at $9.41 on Wednesday. The firm’s 50 day moving average is $10.06 and its 200-day moving average is $11.33. Flexion Therapeutics has a 1 year low of $7.52 and a 1 year high of $14.39. The firm has a market capitalization of $469.78 million, a price-to-earnings ratio of -3.05 and a beta of 1.64. The company has a current ratio of 4.66, a quick ratio of 4.31 and a debt-to-equity ratio of 12.77.

Flexion Therapeutics (NASDAQ:FLXN) last announced its quarterly earnings data on Tuesday, March 9th. The specialty pharmaceutical company reported ($0.37) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.44) by $0.07. The business had revenue of $26.31 million during the quarter, compared to analyst estimates of $26.60 million. On average, equities research analysts forecast that Flexion Therapeutics will post -2.6 earnings per share for the current fiscal year.

In other Flexion Therapeutics news, insider Melissa Layman sold 2,624 shares of the stock in a transaction on Thursday, January 28th. The shares were sold at an average price of $12.55, for a total value of $32,931.20. Following the completion of the sale, the insider now owns 91,000 shares in the company, valued at $1,142,050. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 17.03% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Eudaimonia Partners LLC acquired a new stake in shares of Flexion Therapeutics during the 3rd quarter worth about $36,000. Fort Pitt Capital Group LLC acquired a new stake in shares of Flexion Therapeutics during the 4th quarter worth about $46,000. ExodusPoint Capital Management LP acquired a new stake in shares of Flexion Therapeutics during the 4th quarter worth about $116,000. Virtu Financial LLC acquired a new stake in shares of Flexion Therapeutics during the 4th quarter worth about $117,000. Finally, Exane Derivatives acquired a new stake in shares of Flexion Therapeutics during the 4th quarter worth about $121,000.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.

Further Reading: What is the Moving Average Convergence Divergence (MACD) oscillator?

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.